Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01943422 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
A Phase 1 study, sponsored by John Kirkwood.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01943422: Completed Phase 1 study, sponsored by John Kirkwood.
NCT01943422 is a Phase 1 study that has completed, run by John Kirkwood. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01943422, a Phase 1 study, has completed, sponsored by John Kirkwood.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a dose-seeking and efficacy study of combined BRAF Inhibitor Vemurafenib and High-dose Interferon alfa-2b for therapy of advanced melanoma.
Primary Outcome
At each dose level, the number of patients experiencing Adverse Events over their course of treatment will be characterized by type of Adverse Event and grade using NCI CTCAE (v4.0), and by time of onset in relation to the first day of therapy.
Interventions
- DRUG Vemurafenib
- DRUG High-dose Interferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
What the finished NCT01943422 record still lists
NCT01943422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Vemurafenib is the first listed.
NCT01943422 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01943422 about?
NCT01943422 is a clinical study titled "Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma". This is a dose-seeking and efficacy study of combined BRAF Inhibitor Vemurafenib and High-dose Interferon alfa-2b for therapy of advanced melanoma.
What is the current status of trial NCT01943422?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2013-10. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01943422?
The interventions under investigation include: Vemurafenib (DRUG), High-dose Interferon alfa-2b (DRUG).
Who is sponsoring clinical trial NCT01943422?
This trial is sponsored by John Kirkwood, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01943422's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia